Trials / Terminated
TerminatedNCT01373463
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy
A Phase I Trial of Preoperative Carboplatin or Cisplatin and Pemetrexed With Thoracic Radiation Therapy Followed by Lobectomy in Resectable Stage III Patients With Non-Squamous Non Small Cell Lung Cancer (NSCLC)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study is open to patients that have been diagnosed with non-squamous Stage III Non Small Cell Lung Cancer (NSCLC) and will have surgery to remove the tumor. The purpose of this study is to: * Test a combination of two chemotherapeutic drugs along with radiation therapy, when given prior to surgery and see what effects (good or bad) it has on someone with this type of cancer. Chemotherapeutic drugs selectively destroy diseased cancer cells and tissues. * Test the safety of different dose levels of radiation when given with each combination of chemotherapy; * Determine what side effects are associated with combining radiation with these two chemotherapy combinations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed | Pemetrexed by vein every 21 days for 3 cycles |
| DRUG | Carboplatin | Carboplatin by vein Every 21 days for 3 cycles |
| RADIATION | Radiation Therapy | Radiation treatment 5 days a week for 5-6 weeks. |
| DRUG | Pemetrexed | Pemetrexed by vein every 21 days for 3 cycles |
| DRUG | Cisplatin | Cisplatin by vein every 21 days for 3 cycles |
| RADIATION | Radiation Therapy | Radiation treatment 5 days a week for 5-6 weeks. |
| PROCEDURE | Lobectomy | Surgery |
| PROCEDURE | Lobectomy | Surgery to remove a portion of the lung where the tumor is located. |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2011-06-15
- Last updated
- 2012-07-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01373463. Inclusion in this directory is not an endorsement.